A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)

Phase II multicenter study investigated the efficacy and toxicity of the novel halogenated derivative of sulfaquixonaline Chloroquinoxaline Sulfonamide (CQS) in metastatic colorectal cancer. Eligible patients with metastatic or recurrent colorectal cancer received CQS at a dose schedule of 2000 mg/m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2006-07, Vol.24 (4), p.343-346
Hauptverfasser:	Bekaii-Saab, Tanios S, Mortazavi, Amir, Hicks, Lee G, Zalupski, Mark, Pelley, Robert J, Chan, Kenneth K, Kraut, Eric H
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Cancer therapies Cell cycle Chemotherapy Colorectal cancer Colorectal Neoplasms - drug therapy Dose-Response Relationship, Drug Drug dosages Female Hematology Humans Hypoglycemia Lung cancer Male Metastasis Neoplasm Metastasis Oncology Patients Plasma Quinoxalines - administration & dosage Quinoxalines - adverse effects Quinoxalines - pharmacokinetics Quinoxalines - therapeutic use Sulfanilamides - administration & dosage Sulfanilamides - adverse effects Sulfanilamides - pharmacokinetics Sulfanilamides - therapeutic use Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!